PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Pancreatic Insufficiency, Pancreatic Cancer, Pancreatic Enzyme Abnormality

In brief

Does pancreas enzyme replacement (PERT) decrease weight loss and improve quality of life in patients with unresectable pancreatic cancer?

Key facts

Study ID

NCT02985801

Run by

Massimo Raimondo, M.D.

People needed

16

Starts

2016-12-01

Expected to finish

2019-04-01

Last updated by the study team

2021-03-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients 18-80 years
• Underlying pancreatic adenocarcinoma, unresectable (local invasion or distant metastasis)
• On established chemotherapy regimen for pancreas cancer, which will be continued over the time of study
• Fecal elastase-1 test (FE1) less than 200 mcg pancreatic elastase/g stool

You may not qualify if…

• Common bile duct obstruction resulting in obstructive jaundice
• Celiac disease
• Crohn's disease
• Benign pancreatic conditions
• Bowel obstruction
• Surgically altered bowel anatomy

Where it is running

• Mayo Clinic — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.